GlassScriptPhysician profile
Rubin Pradhan
NPI 1245785054
$673.92
in general payments reported to CMS, 2019-2025
14 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $32.41 · 2022: $125 · 2023: $135 · 2024: $122 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $517.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $516.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $178.61 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Mannkind Corporation | $134.99 | 2023 | Afrezza |
| Sequel Med Tech, LLC | $80.18 | 2025 | Twiist |
| Pfizer INC. | $55.45 | 2024-2025 | |
| Lilly USA, LLC | $38.64 | 2024-2025 | Mounjaro, Zepbound |
| Radius Health, INC. | $33.43 | 2025 | Tymlos |
| Chiesi USA, INC. | $28.56 | 2025 | Mycapssa |
| Xeris Pharmaceuticals, INC. | $24.84 | 2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $18.17 | 2020 | |
| Amgen INC. | $17.82 | 2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $17.37 | 2025 | |
| Ascendis Pharma Endocrinology INC | $16.04 | 2025 | Yorvipath |
| Tandem Diabetes Care, INC. | $15.58 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbvie INC. | $14.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rubin Pradhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.